Pioglitazone inhibits toll-like receptor expression and activity in human monocytes and db/db mice

Mohan R. Dasu, Samuel Park, Sridevi Devaraj, Ishwarlal Jialal

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Toll-like receptors (TLRs) are key innate immune sensors of endogenous damage signals and play an important role in inflammatory diseases like diabetes and atherosclerosis. Pioglitazone (PIO), a peroxisome proliferator-activated receptor (PPAR)-γ agonist, has been reported to be an antiinflammatory agent. Thus, in the present study, we examined the antiinflammatory effects of PIO on TLR2 and TLR4 expression in human monocytes exposed to Pam3CSK4 (Pam; TLR2 ligand) and purified lipopolysaccharide (LPS; TLR4 ligand) using flow cytometry and real-time RT-PCR. Monocytes were isolated from healthy human volunteers and pretreated with PIO (1 μM) followed by Pam (170 ng/ml) and LPS (160 ng/ml) challenge. PIO significantly decreased Pam- and LPS-induced TLR2 (-56%) and TLR4 (-78%) expression (P < 0.05). In addition, PIO decreased TLR ligand-induced nuclear factor-κB activity (-63%), IL-1β (-50%), IL-6 (-52%), monocyte chemoattractant protein-1 (-83%), and TNF-α (-87%) compared with control. Next, PIO-treated db/db mice (n = 6/group) showed decreased TLR2 (-60%) and TLR4 (-45%) expression in peritoneal macrophages compared with vehicle control mice (P < 0.001) with associated decrease in MyD88-dependent signaling and nuclear factor-κB activation. Data suggest that Pam- and LPS-induced TLR2 and TLR4 expression are inhibited by PIO in human monocytes and db/db mice. Thus, we define a novel pathway by which PIO could induce antiinflammatory effects.

Original languageEnglish (US)
Pages (from-to)3457-3464
Number of pages8
JournalEndocrinology
Volume150
Issue number8
DOIs
StatePublished - Aug 2009

Fingerprint

pioglitazone
Toll-Like Receptors
Human Activities
Monocytes
Anti-Inflammatory Agents
Ligands
Peroxisome Proliferator-Activated Receptors
Chemokine CCL2
Peritoneal Macrophages
Interleukin-1

ASJC Scopus subject areas

  • Endocrinology

Cite this

Pioglitazone inhibits toll-like receptor expression and activity in human monocytes and db/db mice. / Dasu, Mohan R.; Park, Samuel; Devaraj, Sridevi; Jialal, Ishwarlal.

In: Endocrinology, Vol. 150, No. 8, 08.2009, p. 3457-3464.

Research output: Contribution to journalArticle

Dasu, Mohan R. ; Park, Samuel ; Devaraj, Sridevi ; Jialal, Ishwarlal. / Pioglitazone inhibits toll-like receptor expression and activity in human monocytes and db/db mice. In: Endocrinology. 2009 ; Vol. 150, No. 8. pp. 3457-3464.
@article{eb79bdb01bab487c8a28a63cc5ab90d9,
title = "Pioglitazone inhibits toll-like receptor expression and activity in human monocytes and db/db mice",
abstract = "Toll-like receptors (TLRs) are key innate immune sensors of endogenous damage signals and play an important role in inflammatory diseases like diabetes and atherosclerosis. Pioglitazone (PIO), a peroxisome proliferator-activated receptor (PPAR)-γ agonist, has been reported to be an antiinflammatory agent. Thus, in the present study, we examined the antiinflammatory effects of PIO on TLR2 and TLR4 expression in human monocytes exposed to Pam3CSK4 (Pam; TLR2 ligand) and purified lipopolysaccharide (LPS; TLR4 ligand) using flow cytometry and real-time RT-PCR. Monocytes were isolated from healthy human volunteers and pretreated with PIO (1 μM) followed by Pam (170 ng/ml) and LPS (160 ng/ml) challenge. PIO significantly decreased Pam- and LPS-induced TLR2 (-56{\%}) and TLR4 (-78{\%}) expression (P < 0.05). In addition, PIO decreased TLR ligand-induced nuclear factor-κB activity (-63{\%}), IL-1β (-50{\%}), IL-6 (-52{\%}), monocyte chemoattractant protein-1 (-83{\%}), and TNF-α (-87{\%}) compared with control. Next, PIO-treated db/db mice (n = 6/group) showed decreased TLR2 (-60{\%}) and TLR4 (-45{\%}) expression in peritoneal macrophages compared with vehicle control mice (P < 0.001) with associated decrease in MyD88-dependent signaling and nuclear factor-κB activation. Data suggest that Pam- and LPS-induced TLR2 and TLR4 expression are inhibited by PIO in human monocytes and db/db mice. Thus, we define a novel pathway by which PIO could induce antiinflammatory effects.",
author = "Dasu, {Mohan R.} and Samuel Park and Sridevi Devaraj and Ishwarlal Jialal",
year = "2009",
month = "8",
doi = "10.1210/en.2008-1757",
language = "English (US)",
volume = "150",
pages = "3457--3464",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "8",

}

TY - JOUR

T1 - Pioglitazone inhibits toll-like receptor expression and activity in human monocytes and db/db mice

AU - Dasu, Mohan R.

AU - Park, Samuel

AU - Devaraj, Sridevi

AU - Jialal, Ishwarlal

PY - 2009/8

Y1 - 2009/8

N2 - Toll-like receptors (TLRs) are key innate immune sensors of endogenous damage signals and play an important role in inflammatory diseases like diabetes and atherosclerosis. Pioglitazone (PIO), a peroxisome proliferator-activated receptor (PPAR)-γ agonist, has been reported to be an antiinflammatory agent. Thus, in the present study, we examined the antiinflammatory effects of PIO on TLR2 and TLR4 expression in human monocytes exposed to Pam3CSK4 (Pam; TLR2 ligand) and purified lipopolysaccharide (LPS; TLR4 ligand) using flow cytometry and real-time RT-PCR. Monocytes were isolated from healthy human volunteers and pretreated with PIO (1 μM) followed by Pam (170 ng/ml) and LPS (160 ng/ml) challenge. PIO significantly decreased Pam- and LPS-induced TLR2 (-56%) and TLR4 (-78%) expression (P < 0.05). In addition, PIO decreased TLR ligand-induced nuclear factor-κB activity (-63%), IL-1β (-50%), IL-6 (-52%), monocyte chemoattractant protein-1 (-83%), and TNF-α (-87%) compared with control. Next, PIO-treated db/db mice (n = 6/group) showed decreased TLR2 (-60%) and TLR4 (-45%) expression in peritoneal macrophages compared with vehicle control mice (P < 0.001) with associated decrease in MyD88-dependent signaling and nuclear factor-κB activation. Data suggest that Pam- and LPS-induced TLR2 and TLR4 expression are inhibited by PIO in human monocytes and db/db mice. Thus, we define a novel pathway by which PIO could induce antiinflammatory effects.

AB - Toll-like receptors (TLRs) are key innate immune sensors of endogenous damage signals and play an important role in inflammatory diseases like diabetes and atherosclerosis. Pioglitazone (PIO), a peroxisome proliferator-activated receptor (PPAR)-γ agonist, has been reported to be an antiinflammatory agent. Thus, in the present study, we examined the antiinflammatory effects of PIO on TLR2 and TLR4 expression in human monocytes exposed to Pam3CSK4 (Pam; TLR2 ligand) and purified lipopolysaccharide (LPS; TLR4 ligand) using flow cytometry and real-time RT-PCR. Monocytes were isolated from healthy human volunteers and pretreated with PIO (1 μM) followed by Pam (170 ng/ml) and LPS (160 ng/ml) challenge. PIO significantly decreased Pam- and LPS-induced TLR2 (-56%) and TLR4 (-78%) expression (P < 0.05). In addition, PIO decreased TLR ligand-induced nuclear factor-κB activity (-63%), IL-1β (-50%), IL-6 (-52%), monocyte chemoattractant protein-1 (-83%), and TNF-α (-87%) compared with control. Next, PIO-treated db/db mice (n = 6/group) showed decreased TLR2 (-60%) and TLR4 (-45%) expression in peritoneal macrophages compared with vehicle control mice (P < 0.001) with associated decrease in MyD88-dependent signaling and nuclear factor-κB activation. Data suggest that Pam- and LPS-induced TLR2 and TLR4 expression are inhibited by PIO in human monocytes and db/db mice. Thus, we define a novel pathway by which PIO could induce antiinflammatory effects.

UR - http://www.scopus.com/inward/record.url?scp=67651166868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651166868&partnerID=8YFLogxK

U2 - 10.1210/en.2008-1757

DO - 10.1210/en.2008-1757

M3 - Article

C2 - 19389833

AN - SCOPUS:67651166868

VL - 150

SP - 3457

EP - 3464

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 8

ER -